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A dysregulated host immune response significantly contributes to 
morbidity and mortality in tuberculous meningitis (TBM). Effective 
host directed therapies (HDTs) are critical to improve survival and 
clinical outcomes. Currently only one HDT, dexamethasone, is proven 
to improve mortality. However, there is no evidence dexamethasone 
reduces morbidity, how it reduces mortality is uncertain, and it has no 
proven benefit in HIV co-infected individuals. Further research on 
these aspects of its use, as well as alternative HDTs such as aspirin, 
thalidomide and other immunomodulatory drugs is needed. Based on 
new knowledge from pathogenesis studies, repurposed therapeutics 
which act upon small molecule drug targets may also have a role in 
TBM. Here we review existing literature investigating HDTs in TBM, 
and propose new rationale for the use of novel and repurposed drugs. 
We also discuss host variable responses and evidence to support a 
personalised approach to HDTs in TBM.
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Introduction
Clinical outcomes in tuberculous meningitis (TBM) depend 
upon both killing Mycobacterium tuberculosis (M.tb) and man-
aging host inflammatory response. Antimicrobial drug therapy 
for TBM has been adapted from that used for pulmonary tuber-
culosis (TB); four drugs are given initially, with subsequent 
tapering to two or three drugs (in drug-susceptible TBM, 
dependent on local guidelines) for continuation of therapy up 
to one year. Yet the host immune response may be dysregu-
lated, and contributes to the poor outcomes associated with 
TBM. Host directed therapies (HDTs) seek to control this 
host response and reduce death and neurological injury.
The discovery and assessment of new therapeutics in TBM 
has been a neglected area; this includes the development of 
bespoke antitubercular drug regimens that account for differing 
ability of drugs to penetrate the central nervous system (CNS), 
and the design of HDTs that counter dysregulated immune 
responses to M.tb within the CNS. In fact, corticosteroids are 
the only widely used host directed therapy in TBM with any 
proven benefit in both adults1 and children2. In adults, in 
particular, questions around their clinical use remain, includ-
ing whether they have a role in improving outcomes in 
HIV-associated TBM and the mechanisms by which they 
improve survival. Clinical trials to assess the efficacy of other 
HDTs including aspirin and thalidomide have been conducted; 
however, there is not yet conclusive evidence to suggest when, 
with whom and at what dose they may be effective. New 
knowledge from studies uncovering mechanisms of inflamma-
tion and brain injury may also allow for a directed approach 
to modulating the host response. Similarly, studies aiming to 
contribute knowledge of factors at play that influence vari-
ability in the host may lead us away from a ‘one size fits all’ 
therapeutic approach.
We review the evidence on currently used HDTs in TBM and 
suggest potential therapeutics based on pathogenesis stud-
ies and drawing from knowledge and experience in other forms 
of tuberculosis and neuroinflammatory conditions. We will 
review work that has contributed to our understanding of vari-
ation in host response and discuss how this knowledge might be 
harnessed to design a personalised approach to the use of 
HDT in TBM.
Existing host directed therapies for tuberculous 
meningitis
Dexamethasone
Adjunctive corticosteroids reduce mortality from TBM, at least 
in the short term1,3,4. The mechanism through which corticos-
teroids confer clinical benefit is unclear, although reduction in 
intracerebral inflammation seems most likely. Glucocorticoids 
bind to and activate the glucocorticoid receptor of macro-
phages and other cells, interfering with inflammatory mediator 
transcription and expression5. Additional indirect genomic 
effects of inhibition of pro-inflammatory transcription fac-
tors such as activator protein-1, and non-genomic mechanisms 
further mediate glucocorticoid anti-inflammatory effects6–9.
Murine studies suggest M.tb induces activation of the micro-
glial NLRP3 inflammasome, a multimolecular immune com-
plex of receptors and sensors that mediates innate immune 
responses and induces inflammation via pro-inflammatory cas-
pases and cytokines; a process inhibited by dexamethasone10,11. 
In TBM, pro-inflammatory cerebrospinal fluid (CSF) cytokine 
concentrations are acutely elevated, although therapeutically 
reducing these concentrations may not be clinically benefi-
cial. In a study of 16 individuals with TBM in India, concentra-
tions of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, 
IL-6, IL-8, IL-10 were elevated in TBM vs. controls, and 
declined during TB treatment, yet cytokine concentrations 
were not related to disease severity, brain magnetic reso-
nance imaging (MRI) abnormalities or clinical outcome12. In 
a paediatric study (n=30), CSF TNF-α, IL-1β, and interferon 
(IFN)-gamma concentrations were elevated in acute TBM, but 
again did not correlate with disease severity, nor were they 
influenced by corticosteroid administration13. However, in a 
large study of clinical and intracerebral inflammatory phe-
notype and nine-month survival in adults with TBM from 
Vietnam, multiple pro-inflammatory and anti-inflammatory CSF 
cytokines were significantly reduced in HIV uninfected indi-
viduals who died vs. in HIV uninfected who survived14. This 
effect (lower pro-inflammatory cytokines in individuals who 
died) was not seen in HIV co-infection. 
In 545 Vietnamese individuals >14 years recruited to a rand-
omized placebo-controlled trial of dexamethasone for TBM, 
dexamethasone was associated with a reduced risk of death 
(relative risk 0.69, p=0.01)1. In a representative subset of this 
study, dexamethasone did not significantly alter tested CSF 
cytokines (TNF-α, IL-1β, IL-6, IL-8, IL-10, IL-12) over time 
vs. placebo15. CSF concentrations of IL-6, IL-8, and IL-10 fell 
slowly after commencement of anti-TB chemotherapy, and 
TNF-α fell rapidly, all irrespective of dexamethasone treatment. 
In a subgroup of HIV uninfected adults (n=37), dexamethasone 
significantly reduced CSF matrix metalloproteinase-9 (MMP-9) 
in follow up samples taken after a median five days of 
treatment16. Further work is required to determine whether the 
protective effect of dexamethasone with a measurable reduction 
in intracerebral inflammation.
International guidelines recommend adjunctive corticosteroids 
for TBM management17. Corticosteroid use in TBM is common-
place, dexamethasone is commonly used as it is affordable and 
widely available although the optimal corticosteroid prepara-
tion, dose, and route of administration are unknown18. Whether 
beneficial therapeutic effects extend to HIV co-infected indi-
viduals is uncertain. In a HIV-positive subgroup (n=98) from 
a randomized trial of adjunctive corticosteroids for TBM in 
Vietnamese adults, dexamethasone was associated with a non- 
significant trend towards improved survival1. Subsequently, 
a study of adults with HIV-associated TBM showed global 
increase in pro-inflammatory cytokine concentrations, running 
counter to theory that immunosuppressed HIV co-infected indi-
viduals have lower intracerebral inflammation14. A multicentre 
randomized controlled trial of adjunctive corticosteroids for 
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HIV co-infected adults with TBM is currently underway in 
Vietnam and Indonesia (NCT03092817)19.
Corticosteroids are frequently used to treat common neuro-
complications of TBM; paradoxical reactions, and the immune 
reconstitution inflammatory syndrome (IRIS). Paradoxical 
neuro-inflammatory reactions, which occur despite appropriate 
anti-TB chemotherapy, may reflect host response to dead and 
dying bacteria20. TBM-IRIS is a common and often severe c 
omplication of starting antiretroviral therapy (ART) in TBM, 
and is associated with high CSF neutrophil counts and a 
positive M.tb culture at presentation21. Interestingly, a CSF 
inflammatory process, specifically high neutrophils and high 
TNF-α in combination with low IFN-gamma, predicted later 
TBM-IRIS in a study of 34 individual with TBM in South 
Africa21. Inflammasome activation appears to be involved 
in the development of TBM-IRIS, with MMP-9 a possible 
mediator of brain tissue damage11. Whilst corticosteroids dur-
ing the first four weeks after initiation of ART reduced TB- 
associated IRIS in HIV co-infected individuals in a trial in 
South Africa, individuals with TBM were excluded22. There are 
no randomized trials of corticosteroid therapy for TBM-IRIS, 
nor for paradoxical neurological reactions in HIV uninfected 
individuals. Table 1 summarises the current evidence for 
dexamethasone use in TBM, as well as for other host-directed 
therapies.
In childhood TBM, benefit from corticosteroids has been dem-
onstrated in a number of studies2,23–25. Unlike in adults, improve-
ment in disability, albeit moderate, is described3. Dosage and 
duration, however, is debated and in randomized trials dosage 
has varied between 1mg/kg and 4mg/kg daily, for 3–4 weeks. 
One trial compared three dosage regimens; 2 mg/kg/day over 
four weeks vs 4 mg/k/day over one week and 2 mg/k/day for 
the next three weeks vs 4 mg/kg/day over four weeks26. In 
each group the initial four weeks was followed by four weeks of 
tapering. There was no difference in mortality between groups; 
however, prolonged periods of higher dose prednisolone were 
associated with new onset optic neuropathy and hydrocephalus26. 
These findings highlight the delicate balance between moder-
ating host immunity and avoiding the occurrence of adverse 
events. Further studies are needed to identify ideal dos-
age regimen, as well as explore host variability in response to 
corticosteroids in childhood TBM.
Table 1. Summary of clinical studies investigating the efficacy of dexamethasone, aspirin and thalidomide in TBM.




Aspirin 81 mg vs. 











No difference in two-month mortality. 
Subgroup analysis showed reduction in 
infarcts and death with aspirin 81 mg (15%) 
and 1000 mg (11%) compared to placebo 
(34%); p = 0.06







Decreased three-month mortality (21.7%) 
vs placebo (43.4%); odds ratio = 3.17, 95%CI 
1.21 - 8.31. Aspirin resulted in absolute risk 
reduction of stroke in 19.1% and significant 
reduction in mortality compared to placebo 
(21.7% vs 43.4%, p=0.02).
Misra29 Aspirin 150mg Retrospective cohort n=135 Mortality
Non-statistical reduction in deaths (25%) 
at three months compared to standard TB 
treatment (17%).
Schoeman30 Aspirin 75mg or 100mg/kg RCT
Children  
n=146
No improved neurological or cognitive 
outcomes or survival with aspirin.







Reduced CSF TNF-α in children with stage 2 
TBM.
Schoeman32 Thalidomide 24mg/kg for one month RCT: double-blind
Children  
n=47
Discontinued prematurely due to side effects 










Reduced risk of death through nine 








Dexamethasone did not significantly alter 
tested CSF cytokines (TNF-α, IL-1β, IL-6, IL-8, 
IL-10, IL-12) over time vs. placebo.
RCT, randomised clinical trial; IL, interleukin; TNF, tumor necrosis factor; TBM, tuberculous meningitis; TB, tuberculosis; CSF, cerebrospinal fluid.
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Aspirin
Cerebral infarction occurs in 25–71% of TBM cases27,33, and 
stroke was associated with a two-fold increase in mortality 
in a recent meta-analysis34. The inflammatory state occurring 
in TBM contributes to the pathogenesis of stroke. A prospec-
tive study of 146 TBM patients demonstrated an acute phase 
inflammatory response with significantly elevated cytokines 
(e.g. IL-2, IL-4, IL-6, IL-1β, IFN-γ, TNF- α) in blood and CSF35. 
A hypercoagulable state was reflected by elevated protein C, 
factor VII, plasminogen activator inhibitor-1 and anticardioli-
pin antibodies, as well as decreased protein S in a case series of 
16 children. Bleeding times were also markedly shorter and 
platelet counts remained markedly raised in this subgroup36. 
Hypercoagulability has been shown to occur in adults with 
pulmonary tuberculosis, and may also contribute to pathogenesis 
of stroke in TBM. Local intra- and extra-vascular factors 
contributes to TBM pathogenesis, most significantly in the form 
of cerebral vasculitis secondary to inflammatory infiltrates; 
initially believed to be directly due to tubercle bacilli implanta-
tion, now known to correlate with the inflammatory exudate in 
the basal cisterns and subarachnoid space37,38. The significance 
of intravascular thrombosis is still unclear. While thrombosis 
might be common in the context of vasculitis, autopsies on TBM 
patients failed to demonstrate frequent arterial thrombosis37. 
Significant platelet dysfunction has also been demonstrated in 
TBM, manifesting as increased mean platelet volumes, platelet 
distribution width and platelet-large cell ratio39. These param-
eters are significantly associated with infarcts and suggests 
the use of antiplatelet agents in TBM39. Local intra- and extra- 
vascular factors contribute to TBM pathogenesis in the form of 
vasculitis due to bacilli infiltration. In an effort to reduce mor-
tality and long-term neurological disability in TBM, aspirin 
is increasingly being studied due to its anti-inflammatory and 
inhibitory effects on platelet and thrombus production. In 
murine models, low dose aspirin (3 mg/kg) showed a systemic 
decrease in serum cytokines (e.g. TNF-α, IL-6, IL-1β) and late 
stage T cell responses in M.tb infection. Aspirin also enhances 
T helper cell 1 responses for eliminating bacilli from lungs40.
To date, three randomized controlled trials have investigated the 
role of aspirin in adult and paediatric TBM. In 118 adult TBM 
patients in India, aspirin resulted in absolute risk reduction of 
stroke in 19.1% and significant reduction in mortality com-
pared to placebo (10 of 118 (21.7%) versus 23 of 118 (43.4%), 
p=0.02)28. A randomised controlled trial of TBM involving 
children in South Africa (n=146) could not establish improved 
neurological/cognitive outcomes or survival with aspirin at 
doses of 75 mg (low dose) or 100 mg/kg/day (high dose)30. 
However, the developmental outcome of children on high dose 
aspirin was similar to the placebo and low dose aspirin groups, 
despite being younger of age and having higher baseline sever-
ity. This finding warrants further investigation of high-dose 
aspirin in childhood TBM. A study of 120 Vietnamese adults 
with TBM demonstrated a reduction in death and new infarcts 
with the addition of 81 mg/day aspirin (8 of 36 or 22.2%) and 
1000 mg/day aspirin (6 of 38 or 15.8%), versus placebo 
(11 of 38 or 28.9%)27. Aspirin was associated with dose- 
dependent inhibition of thromboxane A2 and upregulation of 
pro-resolving protectins in the CSF. Another retrospective study 
by Misra et al. in India failed to validate clinical benefit, show-
ing an insignificant reduction in deaths with the addition of 
150 mg aspirin as compared to standard anti-TB therapy29. 
However, 25% (11 of 135) of patients randomized to the aspirin 
arm had a complete recovery at three months versus 17.1% (7 
of 135) in the standard treatment arm. In the three adult trials, 
corticosteroids were administered alone or in conjunction with 
aspirin with no adverse event signal found. None of these trials 
observed an increase in adverse events, but safety concerns 
with increasing doses of aspirin persist. Whilst these studies 
of adjunctive aspirin described varying results regarding 
morbidity and mortality, they paved the way for further large 
randomised controlled trials. Phase 2 (NCT03927313) and 
3 (NCT04145258) trials are currently underway to validate 
aspirin as a host-directed therapy. Given the insufficient 
evidence base, aspirin is not routinely used in most individuals 
with TBM.
Thalidomide
Thalidomide has a wide range of biological effects, due to its 
ability to interfere with the immune system, and depending on 
the cell type or pathway of activation. The inhibition of TNF-α, 
which is produced primarily by macrophages and monocytes, 
accounts for most of the immunological effects of the drug. 
TNF-α performs a delicate balancing act during host response 
to M.tb infection, whereby on the one hand it is mandatory 
for keeping infection under control, but on the other hand, 
if produced at too high levels it induces a hyperinflamma-
tory state resulting in severe tissue damage. The potential of 
thalidomide to activate T-cells, resulting in elevated produc-
tion of IL2, IFN and TNF-α, may potentially interfere with 
its anti-inflammatory properties41. In addition, thalidomide 
does not inhibit TNF-α produced by stimulated T-cells. The 
therapeutic effect of thalidomide therefore appears to be dose 
dependant since differing TNF-α concentrations will result 
in opposing physiological consequences. 
Thalidomide has been shown to reduce CSF TNF-α experi-
mentally in rabbits42 as well as in children with UK Medical 
Research Council (MRC) grade 2 TBM in a dose-escalating 
pilot study31. However, a double-blind, randomized trial of high 
dose thalidomide treatment (24mg/kg/day for one month) in 
children with grade 2 and 3 TBM was discontinued due to side 
effects (skin rash, hepatitis, neutropenia or thrombocytopenia) and 
deaths in the thalidomide arm32.
The anti-inflammatory benefits of thalidomide (e.g. improved 
resolution of basal enhancement and tuberculomas) noted in 
both the pilot and randomized trials have led to more targeted 
studies, albeit at a much reduced dosage (≤5 mg/kg/day). Addi-
tionally, adjunctive thalidomide has been shown to be particu-
larly effective in observational studies involving tuberculous 
brain abscesses43,44 and blindness-related to optochiasmatic 
arachnoiditis45,46. Adverse drug effects have been less of an 
issue in these situations. The life-threatening nature of these 
TBM sequelae as well as the anatomical location of the lesions, 
which precluded surgery, disqualified them from being included 
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in trials. Nonetheless, the clinical improvements noted have 
been substantial (Figure 1).
When used, the duration of adjunctive thalidomide therapy 
should be guided by subsequent clinical and radiological 
responses. In TB, clinical improvement of mass lesions gener-
ally precedes radiological improvement due to a reduction in 
peri-lesional inflammation. Serial MRI T2-weighted studies 
have shown that evolution of the lesions from early stage “T2 
bright” abscesses with oedema to “T2 black” represents a marker 
of cure44. Regression is associated with fibrosis, mineralization 
(calcification) and eventually disappearance, usually with no 
residual structural abnormalities. T2-black granulomas may, 
however, persist for years in asymptomatic children. In most 
cases, cure is achieved after less than three months of adjunctive 
thalidomide therapy.
It is the authors experience that adjunctive thalidomide war-
rants consideration in the following TBM-related conditions: 
corticosteroid-unresponsive optochiasmatic arachnoiditis result-
ing in visual impairment and/or optic disc pallor; enlarging TB 
abscess despite corticosteroid therapy (TB-IRIS); large TB 
abscess/tuberculomas in critical brain regions (i.e. brainstem) 
that is not amenable to surgical drainage and not responding to 
corticosteroids; large dural-based TB abscess resulting in 
epilepsia partialis.
TNF-α has been shown to exert deleterious effects on capil-
laries already sensitized by exposure to mycobacterial prod-
ucts. The endarteritis, coupled with raised intracranial pressure 
because of edema and obstructive hydrocephalus, often leads to 
cerebral ischaemia/infarction. The value of low-dose adjunctive 
thalidomide in modifying the progressive endarteritis is yet to 
be explored.
Immunomodulatory therapies
Modulation of cytokines known to contribute to pathology is a 
potential strategy to support host defenses or control deleterious 
inflammation in TBM. In TBM, a number of pro-inflammatory 
cytokines are thought to play a role in pathogenesis, includ-
ing IL-2, IL-6, IL-1β, IFN-γ and TNF-α38. However, like in 
other neuroinflammatory conditions where cytokines such 
as IFN-γ have opposing roles47, inhibition of these cytokines 
may not necessarily lead to improved outcomes and there-
fore caution must be exercised in exploring the potential drugs 
that inhibit these pro-inflammatory cytokines as candidate 
HDTs.
There are accumulating data on the role of the anti-TNF-α 
monoclonal antibodies infliximab and adalimumab and the solu-
ble TNF-α receptor etanercept in TBM treatment. Although 
these agents are described as options for treating refractory 
paradoxical reactions involving the CNS48–51, they may also 
be responsible for latent TB reactivation and dissemination to 
the CNS in those where the drug is used to treat autoimmune 
conditions52. Anakinra is a human interleukin-1 receptor antago-
nist that blocks the biological activity of natural IL-1 and may 
also have a role in TBM. Anakinra demonstrated efficacy in 
one case of life-threatening protracted paradoxical inflam-
mation in CNS TB where high dose corticosteroids failed53. 
Other immunomodulatory agents of interest include canakinu-
mab and tocilizumab, human monoclonal antibodies inhibiting 
IL-1 and IL-6, respectively. In TBM, vasculitis occurs due to 
the proximity of the progressive exudative meningitis to the 
Figure 1. CT axial, MRI T2 axial, CT sagittal and MRI T1 post-gadolinium sagittal images at 3–4 month intervals of a 16-month-old 
HIV-infected female with stage III tuberculous meningitis. The initial computed tomography (CT) axial and sagittal scans (A, F) showed 
a large right sided middle cerebral artery infarction, hydrocephalus as well as multiple small rim-enhancing foci in the prepontine cisterns. 
After three months of anti-TB and two months of anti-retroviral therapy, they presented with a depressed level of consciousness. Magnetic 
resonance imaging (MRI) T2 axial (B) and MRI T1 post-gadolinium sagittal (G) demonstrated multiple TB abscesses in the interpeduncular, 
prepontine and chiasmic cisterns (paradoxical HIV related TB IRIS) as well as right cerebral hemisphere spongiotic changes (old infarction). 
Thalidomide was initiated following a poor response to one week of high dose corticosteroids. This resulted in rapid improvement in the 
level of consciousness, gradual decrease in the size of the TB abscesses and loss of T2 signal (i.e. inflammation), which is a marker of cure 
as it represents gradual calcification (C–E & H–J). We confirm that we have obtained consent to use images from the parent/guardian of the 
patient included in this presentation. Permission was obtained in the form of informed written consent. 
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basal subarachnoid cistern and the circle of Willis. Cyclophos-
phamide, an alkylating cytotoxic drug is an effective drug in 
the treatment of primary cerebral vasculitis. Two case reports 
have described clinical improvement with the use of cyclo-
phosphamide in TBM associated cerebral vasculitis54,55; how-
ever, its role as an effective treatment in this context needs 
further investigation, particularly due to concerns over its 
potential adverse activity as a potent immunosuppressive 
drug. Table 2 summarises cases within the published literature 
where these agents have been used in the context of TBM; 
however, pre-clinical and clinical studies to systematically 
investigate the therapeutic effectiveness are required before 
they can be used more widely as adjunctive therapies in TBM.
Antiretroviral therapy
The decision as to when antiretroviral therapy is started must 
consider the potential immunopathogenic complications as 
well as the benefit in preventing further opportunistic infec-
tion. Guidelines vary slightly regarding the timing of initia-
tion of ART relative to initiation of anti-TB chemotherapy in 
those co-infected with TB and HIV. The 2010 World Health 
Organisation (WHO) ART guidelines recommend initiating ART 
within eight weeks of anti-TB chemotherapy in all HIV-TB co-
infected patients regardless of CD4 count56. The U.S. National 
Institutes of Health HIV guidelines recommend starting ART 
within two weeks of anti-TB chemotherapy for HIV-TB co-
infected patients with CD4 cell counts <50 cells/ µL and within 
eight weeks for CD4 counts >50 cells/µL57. In TBM there 
are unique considerations given the infection surrounds cru-
cial structures (the brain and spinal cord) with a very limited 
ability to expand within the skull and spinal canal should 
excess inflammation occur. Inflammation occurring follow-
ing the initiation of HIV therapy is known as immune recon-
stitution inflammatory syndrome (IRIS), which in the context 
of TBM is associated is frequent (up to 40%) and associated 
with high mortality (30%)58,59.
In a randomised trial of testing immediate HIV therapy ini-
tiation (at time of initiating TB treatment) vs delayed (after two 
months) in TBM, immediate therapy was associated with sig-
nificantly more grade 4 adverse events (n=102) than delayed 
HIV therapy (n=87; p=.04). This trial informed current 
Table 2. Biologics and other immunomodulatory therapies in TBM; summary of published case reports.
Reference Drug Dose Mechanism Clinical outcome
Blackmore48 Infliximab 10mg/kg, three 
doses at monthly 
intervals
Anti-TNF Given after four months due to ongoing clinical 
deterioration, despite treatment with dexamethasone 
and cyclophosphamide; resulted in clinical 
improvement. 
Jorge49 Infliximab 10mg/kg, three 
doses at monthly 
intervals
Anti-TNF Young adult with juvenile idiopathic arthritis, treated 
with infliximab developed disseminated TB. With 
stopping of infliximab, neurological deterioration 
occurred with isolation of M.tb in CSF, with no 
improvement with corticosteroids. Infliximab re-
initiation led to neurological improvement. 
Molten50 Infliximab Case 1: 10mg/kg, 
three doses at 
monthly intervals 
Case 2: 5mg/kg, 
three doses at six-
week intervals
Anti-TNF Two cases describing paradoxical worsening 
after initiation of TBM treatment, unresponsive to 
dexamethasone. In both cases, clinical improvement 
occurred following administration of infliximab. 
Abo51 Infliximab 5mg/kg, three doses 
at weeks 1, 3 and 7
Anti-TNF Paradoxical worsening (optochiasmatic arachnoiditis, 
leading to loss of vision) on starting TB treatment in 
a seven-year-old with TBM, despite dexamethasone. 
Clinical improvement occurred following infliximab 
administration. 





Two cases of steroid dependant neurotuberculosis 
(paradoxical worsening when steroids stopped). In both 
cases, patients responded to anakinra therapy. 
A. Gonzalez-
Duarte55












TNF, tumor necrosis factor; TB, tuberculosis; M.tb, Mycobacterium tuberculosis; CSF, cerebrospinal fluid; TBM, tuberculous meningitis.
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consensus that ART initiation should be delayed by between 
4–8 weeks after starting TBM therapy60. This approach hopes 
to strike a balance between the beneficial effects of ART 
(immune reconstitution, control of HIV, prevention of other 
opportunistic infections) and the potential harms of TB-IRIS.
Potential future host directed therapies for 
tuberculous meningitis
Although host directed therapies are in use, they are lim-
ited in either efficacy or availability. Therefore, the quest for 
more effective therapeutics remains ongoing. Here we discuss 
potential therapies that target pathways highlighted in recent 
pathogenesis studies, or draw on insights from other forms of 
TB or inflammatory conditions with shared mechanisms of 
pathogenesis (Figure 2).
Statin therapy
HMG-CoA reductase inhibitors (‘statins’) are ubiquitously 
used in prevention and treatment of cardiovascular disease, but 
are also known to have immunomodulatory, anti-inflammatory 
and anti-oxidative properties. Several in vitro studies have dem-
onstrated that statins enhance anti-inflammatory and inhibit 
pro-inflammatory functions in microglial cells and inhibit mech-
anisms involved in neurodegeneration61–64. Anti-inflammatory 
properties may be due to modulation of isoprenylation65 with 
downstream effects on inhibitory and stimulatory transcrip-
tion pathways, or via allosteric inhibition of leucocyte func-
tion antigen (LFA)-1 integrin66, which is involved in the 
transmigration of activated T cells through the blood brain bar-
rier. Neuroprotective effects may be due to modulation of 
excitotoxicity, vascular function, angiogenesis, and/or reduced 
Figure 2. Schematic of relevant biochemical pathways implicated in development of emerging host directed therapies. A: Drugs 
that reduce glutamate ‘glutamate grabbers’ by increasing breakdown of glutamate (either recombinant glutamic-oxaloacetic transaminase 
(GOT1), or others that mimic its action) may decrease neuro-excitotoxicity associated with brain injury in TBM. B: Phosphodiesterase 
inhibitors reduce breakdown of cAMP to 5’AMP, leading to increased neuronal survival, immune modulation, and increase in axon plasticity 
and myelination. C: Interruption of the tryptophan pathway via modulation of indoleamine 2,3-dioxygenase (IDO) activity may have 
neuroprotective effect, although more data to understand the role of downstream metabolites, particularly the contribution of kyruneic 
acid in antagonism of glutamate receptors, is needed.
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oxidative damage through nitric oxide stimulas67,68. Importantly, 
some studies have shown increased neuronal death with higher 
concentrations of statins69–71.
The potential of statins to effect CNS inflammation and neuro-
degeneration in other conditions are of interest given the shared 
mechanistic pathways in TBM. For example, animal mod-
els of multiple sclerosis (MS) show that statins skew immune 
responses towards an anti-inflammatory T-helper cell 2 response, 
inhibiting pro-inflammatory cytokines IL-2, IL-12 and IFN-γ72. 
Patients with secondary progressive MS benefited from sta-
tin therapy73 and a phase 3 trial is currently underway to 
examine this further (NCT03387670). In a mouse model of 
traumatic brain injury, atorvastatin led to profound attenua-
tion of T cell, neutrophil and natural killer cell invasion into 
the CNS, and reduction in production of pro-inflammatory 
cytokines (IFN-y and IL-6) and chemokines (CCL5 and 
CXCL10)74. In a retrospective observational study, pre-injury 
statin therapy was associated with improved neurological out-
comes in mild traumatic brain injury75; however, in moder-
ate to severe injury no benefit was noted76. In a double-blind 
randomised trial involving 36 patients with traumatic brain 
injury, rosuvastatin given for 10 days in the acute phase of injury 
significantly reduced TNF-α, which correlated with a reduc-
tion in disability scores77. Other conditions where the role of 
statins has been explored include Alzheimer’s disease78, and 
Parkinson’s disease79. Further, statins may be associated with 
reduced risk of tuberculosis80. In a TB murine model, adjunc-
tive simvastatin shortened time to culture clearance by 1 month, 
enhanced bacterial killing, and decreased culture-positive 
relapse and enhance bacterial killing81–83. Clinical trials 
(NCT03456102, NCT04147286) will investigate the efficacy 
of statins in pulmonary tuberculosis. Given their potential use 
as an adjunctive TB therapy, their lipophilic properties allow-
ing good penetration to the CNS, as well as their potential as 
an anti-inflammatory and neuroprotective agent, statins may 
have a role as a HDT in TBM; trials to explore this hypothesis 
are needed.
Glutamate ‘grabbing’ drugs
Excessive glutamate and neuro-excitotoxicity are thought to 
contribute to brain injury and cell death in TBM. In one study, 
RNA sequencing of whole blood and CSF from children with 
TBM demonstrated significant enrichment of transcripts asso-
ciated with neural excitotoxicity predominantly driven by 
glutamate release, NMDA receptor binding and uptake84. This 
mechanism is thought to contribute to brain injury and cell 
death in other neurological conditions such as stroke, epi-
lepsy, traumatic brain injury, Alzheimer’s and Hunting-
ton’s disease85,86. Therapeutics that aim to reduce glutamate 
excitotoxicity either by i) modulating the downstream effects 
of glutamate via NMDA receptor binding or ii) reducing extra-
cellular glutamate (e.g. glutamate ‘grabbing’) may have a role 
in the treatment of TBM. In acute stroke, a similar approach 
was taken; however, although animal studies were promis-
ing, randomised trials in humans assessing efficacy of NMDA 
antagonists largely failed87–89. Therapeutics have been designed 
to reduce glutamate induced excitotoxicity by lowering blood 
glutamate concentration, thus leading to a larger natural gluta-
mate gradient between the brain and blood, thereby facilitating 
the efflux of extracellular brain glutamate into the blood90. 
In an animal study, riboflavin (vitamin B
2
), selected for its 
ability to interact with glutamate-oxaloacetate transaminase 
(GOT), significantly reduced blood glutamate levels com-
pared to placebo (Figure 2A)91. In a randomised trial, riboflavin 
was correlated with improvement of disability when given 
intravenously in adults with acute stroke91. A number of stud-
ies have explored the neuroprotective properties of riboflavin 
including in conditions such as migraine and Parkinson’s 
disease92. It is unclear whether drugs such as riboflavin, or 
others that reduce glutamate neuro-excitotoxicity, have a role as 
an adjunctive therapy to promote neuroprotection in TBM; 
however, given the emerging body of evidence that suggests 
involvement of the glutamate-glutamine pathway, this is a 
potential area of interest for future studies.
Tryptophan pathway drug targets
Tryptophan is an essential amino acid that can either be con-
verted to serotonin or oxidized kynurenines via indoleamine 
2,3-dioxygenase (IDO1) (Figure 2C). Further oxidization occurs 
to convert kynurenine to kynurenic acid, which has neuropro-
tective properties. Prior studies have shown that M.tb induces 
marked upregulation of IDO-1 expression in both human 
and murine macrophages in vitro93, and that blockade of IDO 
activity reduces both clinical manifestations of TB as well as 
microbial and pathological correlates of the human TB syndrome 
in macaques94. In an observational cohort study of TBM, low 
CSF tryptophan levels were found in those who survived, 
compared to non-survivors or controls95. It is therefore unclear 
in TBM whether drugs that block IDO-1 such as indoximod, 
an immunometabolic adjuvant that is current under investi-
gation in cancer therapy96, would cause benefit or harm. It is 
plausible that improved survival seen in those with low CSF 
tryptophan is due to increased availability of kynurenic acid, 
which has neuroprotective action via glutamate receptors and 
reactive oxygen species. Further investigation into the influ-
ence of tryptophan and its downstream metabolites on patho-
genesis in TBM is required in order to establish suitable 
targets along this pathway for HDTs.
Eicosanoid modulating drugs
Eicosanoids are arachidonic acid derived lipid mediators that 
trigger pro-and anti-inflammatory responses and include pros-
taglandins, resolvins, lipoxins, and leukotrienes, which serve as 
signalling molecules, modulating inflammation and cell death 
in TB97. A delicate balance in eicosanoid levels is crucial for 
M.tb control and regulating the production of pro-inflammatory 
cytokines98.
Non-steroidal inflammatory drugs (NSAIDs), which exert their 
effects by inhibiting cyclooxygenase (COX) activity may lead 
to reduction of excessive inflammation in TBM. As discussed, 
aspirin, a non-selective COX inhibitor, has been investigated 
in three trials in TBM with variable outcomes27,28,30. New gen-
eration NSAIDs with more selective inhibition of COX2 may 
have more favourable safety profiles. Phase 1 trials to assess 
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the safety and bactericidal activity of celecoxib and etoricoxib 
in healthy volunteers with a view to developing these agents 
as HDTs for drug sensitive TB are currently underway 
(NCT02602509, NCT02503839). Although trials to further 
investigate the role of aspirin in TBM are underway, future 
research should consider the potential contribution of newer 
more selective COX2 inhibitors in TBM.
Phosphodiesterase inhibitors
Phosphodiesterase inhibitors (PDE-i) are small-molecule inhibi-
tors that reduce inflammation by increasing intracellular cyclic 
adenosine monophosphate and cyclic guanine monophosphate99 
(Figure 2B). Phosphodiesterase 4 (PDE-4) inhibitors such as 
roflumilast have shown to be effective in the treatment of 
numerous inflammatory conditions including chronic obstructive 
inflammatory disease100. PDE-4 is expressed within the cortex 
and hippocampus and animal models suggest that inhibi-
tion of PDE-4 may have a beneficial role in CNS conditions 
where inflammation plays a role in pathogenesis101–105. In ani-
mal models of pulmonary TB, inhibition of PDE-3 (cilostazol), 
PDE-4 (roflumilast) and PDE-5 (sildenafil) have all increased 
bacterial clearance and reduced pro-inflammatory cytokines, 
which contributed to a reduction in neutrophil infiltration and 
lung pathology106–109. The role of phosphodiesterase inhibi-
tors has not been studied in TBM but the properties above 
make them intriguing candidates for adjunctive therapy in TBM. 
Variable host responses and a personalized 
approach
Host immune response to M.tb in TBM is vital, although 
excessive inflammation leads to neurological damage. Poly-
morphisms in genes involved in immune response or signal-
ling pathways can influence host inflammatory response, or 
susceptibility to TBM110.
Previous study in the zebrafish model showed that the leuko-
triene A4 hydrolase (LTA4H) gene influenced the balance of 
pro and anti-inflammatory eicosanoids in response to M.tb 
infection111. LTA4H catalyses the final step in pro-inflammatory 
leukotriene B4 (LTB4) synthesis111, with LTB4 effects usu-
ally balanced by anti-inflammatory lipoxin A4 (LXA4), the two 
together ensuring an appropriate response to M.tb without 
excessive tissue damage112. A single nucleotide polymorphism 
(SNP) (rs17525495) in the promoter region of the LAT4H gene 
alters gene expression, and LTB4 LXA4 balance; low (CC) 
and high (TT) inflammatory states result from LTA4H allele 
homozygosity whereas an intermediate (CT) inflammatory state 
results from allele heterozygosity111. Both TT and CC inflam-
matory states were associated with increased death in a retro-
spective study of adults with TBM113. In this retrospective study 
adjunctive dexamethasone was associated with improved sur-
vival in the high inflammatory TT group, with the effect of 
dexamethasone unclear in the CC and CT groups113. In a subse-
quent study of 764 Vietnamese adults, 10 CSF cytokines were 
measured of: TNF-α, IFN-γ, IL-1β, IL-2, IL4, IL-5, IL-6, IL-10, 
IL-12, IL-1314. In HIV-uninfected adults with TBM, pro-inflam-
matory IL-1β, IL-2, and IL-6 (but not TNF-α) were significantly 
associated with LTA4H genotype; low concentrations in CC 
genotype, intermediate concentrations in CT genotype, and high 
concentrations in TT genotype14. In HIV co-infected individuals 
with TBM, LTA4H genotype did not appear to influence sur-
vival, response to dexamethasone, or CSF cytokine profile14. 
Additionally, LTA4H genotype did not influence survival in a 
study of HIV-uninfected Indonesian adults with TBM, all of 
whom received corticosteroids114. A LTA4H genotype stratified 
approach to adjunctive corticosteroid therapy in TBM is now 
being assessed in an ongoing randomized placebo-controlled 
LTA4H genotype stratified non-inferiority trial of HIV unin-
fected adults with TBM in Vietnam (NCT03100786)115. If benefit 
of adjunctive corticosteroids as a host directed therapy are 
shown to be limited to one or more LTA4H genotypes, this 
paves the way for personalized corticosteroid therapy in TBM.
Where variable host responses to M.tb increase intracerebral 
inflammation, or genetic polymorphisms lead to overexpression 
of a specific molecule or target, targeted personalized therapies 
may be beneficial. In a study of tryptophan genome wide 
SNP data we identified 11 quantitative trait loci associated with 
CSF tryptophan concentrations, and found that these quan-
titative trait loci were predictive of patient survival19. A SNP 
(rs17842268) in CD43, a surface glycoprotein, has been asso-
ciated with more severe presentation, and decreased survival, 
in TBM116. Why SNPs in CD43 affect M.tb susceptibility is 
uncertain, but CD43 has a role in regulating proinflammatory 
cytokines116, and theoretically anti-inflammatory therapies may 
be beneficial in such patients. Evidence that patients with a 
dysregulated host immune response benefit from more, or 
different, host directed therapies is lacking.
Conclusions and key areas for future research
Host directed therapies are an evolving area of TBM research. 
We know that the inflammatory response in TBM contributes to 
poor outcomes. Further, we know that dexamethasone reduces 
death from TBM. What is unknown is how the drug works, 
who might benefit most from dexamethasone or whether other 
therapies should be given in addition to dexamethasone or in 
place of it in some scenarios. There may also be scenarios where 
dexamethasone is harmful. Important questions regarding the 
exact role of thalidomide and aspirin also remain. While in the 
case of the former, a narrow context in which the drug might 
be useful is becoming clearer, in the latter, the optimal and safe 
dose of aspirin, considering its antiplatelet and anti-inflammatory 
properties, is uncertain. Although the use of immunomodulatory 
therapies has been reported sporadically, often where corticoster-
oid treatments have failed, no clinical trials have been conducted 
to systematically assess their safety profile and efficacy.
Drug discovery depends on accurately identifying molecular 
targets that play crucial roles in disease biology, and which 
are amenable to modulation via biologics or small molecule 
drug therapeutics. In diseases with high global incidences 
such diabetes or hypertension, large scale data repositories are 
beginning to provide genetic insights to inform drug discovery 
and therefore change the direction of and speed at which novel 
and repurposed therapeutics become available117. In TBM we 
must work towards establishing similar repositories through 
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international collaboration. However, the relatively low global 
incidence of the disease, and the challenging environments in 
which TBM most commonly occurs will make this a lengthy 
endeavour.
In the near future, we can focus on better understanding of 
key pathogenic processes underpinning inflammation and 
brain injury. For example, further understanding of the role 
and interaction of glutamate and tryptophan in brain injury 
may uncover targets for which existing drugs can be repur-
posed and novel therapeutics developed. The rational design 
of animal models to help inform which of these might deserve 
clinical trials in TBM is also key; although the rabbit model of 
TBM has been in use since the early 1900s118, further research 
is required to establish whether a more refined or alternative 
model could better recapitulate human disease. Genomic research 
to identify variation in host response will allow further 
refinement of therapeutic approaches based on factors at the 
individual patient and population level. While studies of LTA4H 
genotype have led the way in this area of TBM research, focus 
must now widen to include other pathways that are likely to 
vary between hosts. As we move forward with host-directed 
therapies for TBM, we must remain cognisant of the charac-
teristics of the hosts whose responses we are attempting to 
change. Whether these changes are obvious (e.g. HIV infection) 
or more opaque (e.g. unknown genetic polymorphisms), they 
must be considered with trial design so that we can understand 
as fully as possible, the role of these therapies in improving 
outcomes in TBM.
Data availability
No data are associated with this article.
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